Cited by 2,207Cancer Genomics and DiagnosticsBRCA gene mutations in cancerBreast Cancer Treatment Studies

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

Open access

Dawson, Sarah-Jane, Tsui, Dana W.Y., Murtaza, Muhammed, Biggs, Heather, Rueda, Oscar M., Chin, Suet-Feung, Dunning, Mark J., Gale, Davina, Forshew, Tim, Mahler-Araujo, Betania, Rajan, Sabrina, Humphray, Sean, Becq, Jennifer, Halsall, David, Wallis, Matthew, Bentley, David, Caldas, Carlos, Rosenfeld, Nitzan·2013·New England Journal of Medicine

DOI 10.1056/nejmoa1213261

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The management of metastatic breast cancer requires monitoring of the tumor burden to determine the response to treatment, and improved biomarkers are needed. Biomarkers such as cancer antigen 15-3 (CA 15-3) and circulating tumor cells have been widely studied. However, circulating cell-free DNA carrying tumor-specific alterations (circulating tumor DNA) has not been extensively investigated or compared with other circulating biomarkers in breast cancer. METHODS: We compared the radiographic imaging of tumors with the assay of circulating tumor DNA, CA 15-3, and circulating tumor cells in 30 women with metastatic breast cancer who were receiving systemic therapy. We used targeted or whole-genome sequencing to identify somatic genomic alterations and designed personalized assays to quantify circulating tumor DNA in serially collected plasma specimens. CA 15-3 levels and numbers of circulating tumor cells were measured at identical time points. RESULTS: Circulating tumor DNA was successfully detected in 29 of the 30 women (97%) in whom somatic genomic alterations were identified; CA 15-3 and circulating tumor cells were detected in 21 of 27 women (78%) and 26 of 30 women (87%), respectively. Circulating tumor DNA levels showed a greater dynamic range, and greater correlation with changes in tumor burden, than did CA 15-3 or circulating tumor cells. Among the measures tested, circulating tumor DNA provided the earliest measure of treatment response in 10 of 19 women (53%). CONCLUSIONS: This proof-of-concept analysis showed that circulating tumor DNA is an informative, inherently specific, and highly sensitive biomarker of metastatic breast cancer. (Funded by Cancer Research UK and others.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1213261

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1993) · doi:10.1007/978-1-4899-4541-9 · Cited by 21,230
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Self-citation
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,602
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Nagrath, S., Sequist, L. V. D., Maheswaran, S., Bell, D. W., Irimia, D., Ulkus, L., Smith, M. R., Kwak, E. L., Digumarthy, S. R., Muzikansky, A., et al. (2007) · Nature · doi:10.1038/nature06385 · Cited by 3,595
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. �., & Pantel, K. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3066 · Cited by 2,897

Flagged first, then by citations

Show all 44 references

1 of the 44 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Lauro S, 1999, Anticancer Res, 19, 3511
Chen X, 1999, Clin Cancer Res, 5, 2297

Sorted by citations

Items 301–400 of 1,003

Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer
Page, K., Guttery, D. S., Fernández-García, D., Hills, A., Hastings, R. K., Luo, J., Goddard, K. S., Shahin, V., Woodley-Barker, L., Rosales, B. M., et al. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.261834 · Cited by 123
Going with the Flow: From Circulating Tumor Cells to DNA
Bidard, F., Weigelt, B., & Reis-Filho, J. S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006305 · Cited by 123
Circulating nucleic acids as biomarkers in breast cancer
Schwarzenbach, H. (2013) · Breast Cancer Research · doi:10.1186/bcr3446 · Cited by 121
Liquid Biopsy in Breast Cancer: A Focused Review
Tay, T. K. Y., & Tan, P. H. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0559-ra · Cited by 125
Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma
Flach, S., Howarth, K., Hackinger, S., Pipinikas, C., Ellis, P., McLay, K., Marsico, G., Forshew, T., Walz, C., Reichel, C. A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01716-7 · Cited by 119
Self-citation
Circulating tumour DNA (CtDNA) as a liquid biopsy for melanoma
Calapre, L., Warburton, L., Millward, M., Ziman, M., & Gray, E. S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.030 · Cited by 118
Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities
Espósito, A., Bardelli, A., Criscitiello, C., Colombo, N., Gelao, L., Fumagalli, L. A. M., Minchella, I., Locatelli, M., Goldhirsch, A., & Curigliano, G. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.003 · Cited by 121
Circulating cell-free DNA-based epigenetic assay can detect early breast cancer
Uehiro, N., Sato, F., Pu, F., Tanaka, S., Kawashima, M., Kawaguchi, K., Sugimoto, M., Saji, S., & Toi, M. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0788-z · Cited by 117
Non-blood circulating tumor DNA detection in cancer
Peng, M., Chen, C., Hulbert, A., Brock, M. V., & Yu, F. (2017) · Oncotarget · doi:10.18632/oncotarget.19942 · Cited by 119
CUT-PCR: CRISPR-mediated, ultrasensitive detection of target DNA using PCR
Lee, S. H., Yu, J., Hwang, G.-H., Kim, S., Kim, H. S., Ye, S., Kim, K., Park, J., Park, D. Y., Cho, Y.-K., et al. (2017) · Oncogene · doi:10.1038/onc.2017.281 · Cited by 111
Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer
Patel, K., van der Vos, K. E., Smith, C. G., Mouliere, F. C., Tsui, D. W. Y., Morris, J., Chandrananda, D., Marass, F., van den Broek, D. A., Neal, D. E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05623-3 · Cited by 117
Self-citation
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?
Buono, G., Gerratana, L., Bulfoni, M., Provinciali, N., Basile, D., Giuliano, M., Corvaja, C., Arpino, G., Mastro, L. D., Placido, S. D., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.01.004 · Cited by 117
Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA
Chaudhuri, A. A., Binkley, M. S., Osmundson, E. C., Alizadeh, A. A., & Diehn, M. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.05.001 · Cited by 117
Biomarkers in Breast Cancer
Duffy, M. J., Walsh, S. M., McDermott, E. W. M., & Crown, J. P. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.05.001 · Cited by 120
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer
Jeselsohn, R. M., Angelis, C. D., Brown, M. A., & Schiff, R. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0591-8 · Cited by 112
A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma
Labgaa, I., Villacorta-Martín, C., D’Avola, D., Craig, A. J., von Felden, J., Martins-Filho, S. N., Sia, D., Stueck, A., Ward, S. C., Fiel, M. I., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0206-3 · Cited by 117
The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC
Nygaard, A. D., Holdgaard, P. C., Spindler, K.-L. G., Pallisgaard, N., & Jakobsen, A. K. M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.705 · Cited by 115
Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer
Peng, M., Huang, Q., Yin, W., Tan, S., Chen, C., Liu, W., Tang, J., Wang, X., Zhang, B., Zou, M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.561598 · Cited by 116
Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA
Uchida, J., Kato, K., Kukita, Y., Kumagai, T., Nishino, K., Daga, H., Nagatomo, I., Inoue, T., Kimura, M., Oba, S., et al. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.241414 · Cited by 115
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
Collins, D. C., Sundar, R., Lim, J. S. J., & Yap, T. A. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.012 · Cited by 116
Characterization of the release and biological significance of cell-free DNA from breast cancer cell lines
Wang, W. T., Kong, P., Ma, G., Li, L., Zhu, J., Xia, T., Xie, H., Zhou, W., & Wang, S. (2017) · Oncotarget · doi:10.18632/oncotarget.17858 · Cited by 114
Droplet-Based Digital PCR
Perkins, G., Lu, H., Garlan, F., & Taly, V. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.10.001 · Cited by 114
Circulating DNA as biomarker in breast cancer
Schwarzenbach, H., & Pantel, K. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0645-5 · Cited by 113
Strategies for modern biomarker and drug development in oncology
Smith, A. D., Roda, D., & Yap, T. A. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0070-8 · Cited by 112
Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing
Liao, W., Yang, H., Xu, H., Wang, Y., Ge, P., Ren, J., Xu, W., Lu, X., Sang, X., Zhong, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9629 · Cited by 112
Biological background of the genomic variations of cf-DNA in healthy individuals
Liu, J., Chen, X., Wang, J., Zhou, S., Wang, C. L., Ye, M. Z., Wang, X. Y., Song, Y., Wang, Y., zhang, L., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy513 · Cited by 117
Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges
Pal, M., Muinao, T., Boruah, H. P. D., & Mahindroo, N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112488 · Cited by 112
Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies
Espósito, A., Criscitiello, C., Locatelli, M., Milano, M., & Curigliano, G. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.007 · Cited by 110
Circulating cell-free DNA for non-invasive cancer management
Stewart, C. M., & Tsui, D. W. Y. (2018) · Cancer Genetics · doi:10.1016/j.cancergen.2018.02.005 · Cited by 109
Self-citation
Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease
Butler, T. M., Johnson-Camacho, K., Peto, M., Wang, N. J., Macey, T. A., Korkola, J. E., Koppie, T. M., Corless, C. L., Gray, J. W., & Spellman, P. T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136407 · Cited by 111
Circulating Tumor DNA Outperforms Circulating Tumor Cells for KRAS Mutation Detection in Thoracic Malignancies
Freidin, M. B., Freydin, M., Leung, M., Montero, Á., Nicholson, A. G., & Lim, E. K. S. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.242453 · Cited by 110
Minimal residual disease in multiple myeloma: bringing the bench to the bedside
Mailankody, S., Korde, N., Lesokhin, A. M., Lendvai, N. K., Hassoun, H., Stetler‐Stevenson, M., & Landgren, O. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.239 · Cited by 111
Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
Oberle, A., Brandt, A. P., Voigtlaender, M., Thiele, B., Radloff, J., Schulenkorf, A., Alawi, M., Akyüz, N., März, M., Ford, C. T., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.161414 · Cited by 110
Nanomaterial Preparation by Extrusion through Nanoporous Membranes
Guo, P., Huang, J., Zhao, Y., Martin, C. R., Zare, R. N., & Moses, M. A. (2018) · Small · doi:10.1002/smll.201703493 · Cited by 110
A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer
Kwan, T. T., Bardia, A., Spring, L. M., Giobbie‐Hurder, A., Kalinich, M., Dubash, T. D., Sundaresan, T. K., Hong, X., LiCausi, J. A., Ho, U. K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0432 · Cited by 113
Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNA
Rowlands, V., Rutkowski, A. J., Meuser, E., Carr, T. H., Harrington, E. A., & Barrett, J. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-49043-x · Cited by 119
Circulating Cell-Free Tumour DNA in the Management of Cancer
Francis, G. D., & Stein, S. R. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160614122 · Cited by 112
Multiplexed detection of serological cancer markers with plasmon-enhanced Raman spectro-immunoassay
Li, M., Kang, J. W., Sukumar, S. V., Dasari, R. R., & Barman, I. (2015) · Chemical Science · doi:10.1039/c5sc01054c · Cited by 107
The feasibility of using mutation detection in ctDNA to assess tumor dynamics
Yi, X., Ma, J., Guan, Y., Chen, R., Yang, L. M., & Xia, X. (2017) · International Journal of Cancer · doi:10.1002/ijc.30620 · Cited by 108
Early Noninvasive Detection of Response to Targeted Therapy in Non–Small Cell Lung Cancer
Phallen, J. A., Leal, A., Woodward, B. D., Forde, P. M., Naidoo, J., Marrone, K. A., Brahmer, J. R., Fiksel, J., Medina, J. E., Cristiano, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1082 · Cited by 108
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies
Russo, A. D., Incorvaia, L., Re, M. D., Malapelle, U., Capoluongo, E., Gristina, V., Castiglia, M., Danesi, R., Fassan, M., Giuffrè, G., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100164 · Cited by 106
Cancer biomarkers and their biosensors: A comprehensive review
Khan, H., Shah, M. R., Barek, J., & Malik, M. I. (2022) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2022.116813 · Cited by 111
Prostate-specific extracellular vesicles as a novel biomarker in human prostate cancer
Park, Y. H., Shin, H., Jung, A. R., Kwon, O. S., Choi, Y. J., Park, J., & Lee, J. Y. (2016) · Scientific Reports · doi:10.1038/srep30386 · Cited by 106
Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer
Oliveira, K. C. D. S., Ramos, I. B., da Silva, J. M. C., Barra, W. F., Riggins, G. J., Palande, V., Pinho, C. T., Frenkel‐Morgenstern, M., Santos, S., de Assumpção, P. P., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0768 · Cited by 108
Monitoring gastric cancer progression with circulating tumour DNA
Hamakawa, T., Kukita, Y., Kurokawa, Y., Miyazaki, Y., Takahashi, T., Yamasaki, M., Miyata, H., Nakajima, K., Taniguchi, K., Takiguchi, S., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.609 · Cited by 105
Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives
Rizzo, A., Ricci, A. D., Tavolari, S., & Brandi, G. (2020) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20203 · Cited by 107
Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring
Pérez-Callejo, D., Romero, A., Provencio, M., & Torrente, M. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.10.07 · Cited by 111
Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies
Tellez-Gabriel, M., Knutsen, E., & Perander, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249457 · Cited by 108
Current commercial dPCR platforms: technology and market review
Tan, L. L., Loganathan, N., Agarwalla, S., Yang, C., Yuan, W., Zeng, J., Wu, R., Wang, W. T., & Duraiswamy, S. (2022) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2022.2037503 · Cited by 109
Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer
Spindler, K. G., Appelt, A. L., Pallisgaard, N., Andersen, R. F., Brandslund, I., & Jakobsen, A. K. M. (2014) · International Journal of Cancer · doi:10.1002/ijc.28946 · Cited by 103
Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer
Wang, Y., Zhao, C., Chang, L., Jia, R., Liu, R., Zhang, Y., Gao, X., Li, J., Chen, R., Xia, X., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.003 · Cited by 101
Genome-wide plasma DNA methylation features of metastatic prostate cancer
Wu, A., Cremaschi, P., Wetterskog, D., Conteduca, V., Franceschini, G. M., Kleftogiannis, D., Jayaram, A., Sandhu, S. K., Wong, S. Q., Benelli, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130887 · Cited by 103
Circulating Biomarkers in Breast Cancer
Seale, K. N., & Tkaczuk, K. H. R. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.09.006 · Cited by 116
Role of ctDNA in Breast Cancer
Sant, M., Bernat‐Peguera, A., Felip, E., & Vila, M. M. (2022) · Cancers · doi:10.3390/cancers14020310 · Cited by 106
Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?
Kidess, E., & Jeffrey, S. S. (2013) · Genome Medicine · doi:10.1186/gm474 · Cited by 104
Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring
Kang, Z., Stevanović, S., Hinrichs, C. S., & Cao, L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1553 · Cited by 105
Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma
Cabel, L., Jeannot, E., Bièche, I., Vacher, S., Callens, C., Bazire, L., Morel, A., Bernard‐Tessier, A., Chemlali, W., Schnitzler, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0922 · Cited by 102
A machine learning approach for somatic mutation discovery
Wood, D. E., White, J. R., Georgiadis, A. P., Emburgh, B. V., Parpart-Li, S. T., Mitchell, J., Anagnostou, V., Niknafs, N., Karchin, R., Papp, E., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7939 · Cited by 101
Sensing of circulating cancer biomarkers with metal nanoparticles
Pallares, R. M., Thanh, N. T. K., & Su, X. (2019) · Nanoscale · doi:10.1039/c9nr03040a · Cited by 103
Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma
Xi, L., Pham, T. H.-T., Payabyab, E. C., Sherry, R. M., Rosenberg, S. A., & Raffeld, M. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0613 · Cited by 104
Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome
Venkatesan, S., & Swanton, C. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158930 · Cited by 106
Diagnostic Performance of Plasma DNA Methylation Profiles in Lung Cancer, Pulmonary Fibrosis and COPD
Wielscher, M., Vierlinger, K., Kegler, U., Ziesche, R., Gsur, A., & Weinhäusel, A. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.06.025 · Cited by 103
Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study
Nair, N., Camacho‐Vanegas, O., Rykunov, D., Dashkoff, M., Camacho, S. C., Schumacher, C. A., Irish, J. C., Harkins, T. T., Freeman, E., Garcia, I., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002206 · Cited by 102
Circulating Tumor DNA: Measurement and Clinical Utility
Donaldson, J. M., & Park, B. H. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-041316-085721 · Cited by 104
Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
Yang, M., Forbes, M. E., Bitting, R. L., O’Neill, S. S., Chou, P. C., Topaloĝlu, Ü., Miller, L. D., Hawkins, G. A., Grant, S. C., DeYoung, B. R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx766 · Cited by 99
A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer
Jiang, R., Lu, Y., Ho, H. H., Li, B., Chen, J., Lin, M., Li, F., Wu, K., Wu, H., Lichterman, J. N., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6330 · Cited by 101
Biomarker Studies in Early Detection and Prognosis of Breast Cancer
Li, G., Hu, J., & Hu, G. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_2 · Cited by 98
Assessment of the Clinical Utility of Plasma Metagenomic Next-Generation Sequencing in a Pediatric Hospital Population
Lee, R. A., Dhaheri, F. A. A., Pollock, N. R., & Sharma, T. S. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00419-20 · Cited by 98
Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening
Adashek, J. J., Jankú, F., & Kurzrock, R. (2021) · Cancers · doi:10.3390/cancers13143600 · Cited by 100
Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma
Yamamoto, Y., Uemura, M., Fujita, M., Maejima, K., Koh, Y., Matsushita, M., Nakano, K., Hayashi, Y., Wang, C., Ishizuya, Y., et al. (2018) · Cancer Science · doi:10.1111/cas.13906 · Cited by 96
Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer
Watanabe, F., Suzuki, K., Tamaki, S., Abe, I., Endo, Y., Takayama, Y., Ishikawa, H., Kakizawa, N., Saito, M., Futsuhara, K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0227366 · Cited by 100
Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes
Shen, T. S., der Stadt, S. P.-V., Yeat, N. C., & Lin, J. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00215 · Cited by 97
Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma
Krumbholz, M., Hellberg, J., Steif, B., Bäuerle, T., Gillmann, C., Fritscher, T., Agaimy, A., Frey, B., Juengert, J., Wardelmann, E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3028 · Cited by 100
Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study
Pécuchet, N., Zonta, E., Didelot, A., Combe, P., Thibault, C., Gibault, L., Lours, C., Rozenholc, Y., Taly, V., Laurent‐Puig, P., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002199 · Cited by 96
Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids
Okajima, W., Komatsu, S., Ichikawa, D., Miyamae, M., Ohashi, T., Imamura, T., Kiuchi, J., Nishibeppu, K., Arita, T., Konishi, H., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i31.5650 · Cited by 98
Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy
Ono, A., Fujimoto, A., Yamamoto, Y., Akamatsu, S., Hiraga, N., Imamura, M., Kawaoka, T., Tsuge, M., Abe, H., Hayes, C. N., et al. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.06.009 · Cited by 97
ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy
Ma, F., Zhu, W., Guan, Y., Yang, L. M., Xia, X., Chen, S., Li, Q., Guan, X., Yi, Z., Qian, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11791 · Cited by 97
Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer
Cavallone, L., Aguilar‐Mahecha, A., Lafleur, J., Brousse, S., Aldamry, M., Roseshter, T., Lan, C., Alirezaie, N., Bareke, E., Majewski, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71236-y · Cited by 95
Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer
Reinert, T., Saad, E. D., Barrios, C. H., & Bines, J. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00026 · Cited by 97
Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study
Ng, C. K. Y., Costanzo, G. G. D., Tosti, N., Paradiso, V., Coto‐Llerena, M., Roscigno, G., Perrina, V., Quintavalle, C., Boldanova, T., Wieland, S. F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy083 · Cited by 94
Hepatitis B Virus DNA Integration Drives Carcinogenesis and Provides a New Biomarker for HBV-related HCC
Yeh, S., Li, C., Lin, Y.-Y., Ho, M., Wang, Y.-C., Tseng, S.-T., & Chen, P. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.01.001 · Cited by 94
Variant allele frequency: a decision-making tool in precision oncology?
Bielo, L. B., Trapani, D., Repetto, M., Crimini, E., Valenza, C., Belli, C., Criscitiello, C., Marra, A., Subbiah, V., & Curigliano, G. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.08.011 · Cited by 100
Circulating DNA of HOTAIR in serum is a novel biomarker for breast cancer
Zhang, L., Song, X., Wang, X., Xie, Y., Wang, Z., Xu, Y., You, X., Liang, Z., & Cao, H. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3431-2 · Cited by 93
Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights
Ng, C. K. Y., Schultheis, A. M., Bidard, F., Weigelt, B., & Reis-Filho, J. S. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv015 · Cited by 96
The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments
Capua, D. D., Bracken-Clarke, D. M., Ronan, K. E., Baird, A., & Finn, S. P. (2021) · Cancers · doi:10.3390/cancers13163923 · Cited by 98
Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer
Hirahata, T., Quraish, R. U., Quraish, A. U., Quraish, S. U., Naz, M., & Razzaq, M. A. (2022) · Cancer Informatics · doi:10.1177/11769351221076062 · Cited by 95
Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia
Yeh, P. S.-H., Hunter, T., Sinha, D., Ftouni, S., Wallach, E., Jiang, D. H. S., Chan, Y.-C., Wong, S. Q., Silva, M. J., Vedururu, R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14756 · Cited by 93
Self-citation
Consensus on precision medicine for metastatic cancers: a report from the MAP conference
Swanton, C., Soria, J., Bardelli, A., Biankin, A. V., Caldas, C., Chandarlapaty, S., de Koning, L., Dive, C., Feunteun, J., Leung, S.-Y., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw192 · Cited by 94
Self-citation
Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations
Iwama, E., Sakai, K., Azuma, K., Harada, T., Harada, D., Nosaki, K., Hotta, K., Ohyanagi, F., Kurata, T., Fukuhara, T., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw531 · Cited by 92
Liquid Biopsies for Cancer: Coming to a Patient near You
Krishnamurthy, N., Spencer, E. G., Torkamani, A., & Nicholson, L. J. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6010003 · Cited by 95
Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models
Mair, R. J., Mouliere, F. C., Smith, C. G., Chandrananda, D., Gale, D. G., Marass, F., Tsui, D. W. Y., Massie, C. E., Wright, A. J., Watts, C., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0074 · Cited by 90
Self-citation
Field cancerization in breast cancer
Gadaleta, E., Thorn, G. J., Ross‐Adams, H., Jones, J. L., & Chelala, C. (2022) · The Journal of Pathology · doi:10.1002/path.5902 · Cited by 97
Liquid biopsies in patients with diffuse glioma
Best, M. G., Sol, N., Zijl, S., Reijneveld, J. C., Wesseling, P., & Würdinger, T. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1399-y · Cited by 94
Precision medicine in pediatric oncology: Lessons learned and next steps
Mody, R. J., Prensner, J. R., Everett, J. N., Parsons, D. W., & Chinnaiyan, A. M. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26288 · Cited by 94
Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis
O’Leary, B., Hrebien, S., Beaney, M., Fribbens, C. V., García-Murillas, I., Jiang, J., Li, Y., Bartlett, C. H., André, F., Loibl, S., et al. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2019.305805 · Cited by 93
Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden
Zhu, G., Guo, Y. A., Ho, D., Poon, P. S. Y., Poh, Z. W., Wong, P., Gan, A., Chang, M. M., Kleftogiannis, D., Lau, Y. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22463-y · Cited by 90
Controls to validate plasma samples for cell free DNA quantification
Pallisgaard, N., Spindler, K. G., Andersen, R. F., Brandslund, I., & Jakobsen, A. K. M. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.04.015 · Cited by 90
Multiscale immunomagnetic enrichment of circulating tumor cells: from tubes to microchips
Chen, P., Huang, Y.-Y., Hoshino, K., & Zhang, X. (2013) · Lab on a Chip · doi:10.1039/c3lc51107c · Cited by 90
The Cellular Origin and Evolution of Breast CancerPreprint
Zhang, M., Lee, A. V., & Rosen, J. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027128 · Cited by 92
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance
Siravegna, G., & Bardelli, A. (2014) · Genome biology · doi:10.1186/s13059-014-0449-4 · Cited by 88

Authors: Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., Rajan, S., Humphray, S., Becq, J., Halsall, D., Wallis, M., Bentley, D., Caldas, C., & Rosenfeld, N.
Affiliations: University of Cambridge (GB)
National Health Service (GB)
ORCID: Dawson, Sarah-Jane
Tsui, Dana W.Y.
Murtaza, Muhammed
Biggs, Heather
Rueda, Oscar M.
Chin, Suet-Feung
Dunning, Mark J.
Gale, Davina
Forshew, Tim
Mahler-Araujo, Betania
Humphray, Sean
Halsall, David
Wallis, Matthew
Caldas, Carlos
Rosenfeld, Nitzan
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-03-28
Volume: 368
Issue: 13
Pages: 1199-1209
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1213261
OpenAlex: W2140575188
Cited by: 2,207
References: 44
Citations by year: 2026: 86 · 2025: 96 · 2024: 106 · 2023: 109 · 2022: 169 · 2021: 180 · 2020: 197 · 2019: 220 · 2018: 197 · 2017: 224 · 2016: 204 · 2015: 195 · 2014: 135 · 2013: 82
FWCI: 72.15
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: Cancer Research UK (11906, 16942, 22310)
National Institute for Health and Care Research (NF-SI-0611-10154)
NIHR Cambridge Biomedical Research Centre
Cancer Research UK Cambridge Institute, University of Cambridge
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: circulating tumor DNA, metastatic breast cancer, liquid biopsy, CA15-3, circulating tumor cells, treatment response monitoring, tumor burden, somatic alterations, circulating biomarkers, early detection of treatment response
MeSH terms: Breast Neoplasms, DNA, Neoplasm, Female, Humans, Mutation, Neoplasm Metastasis, Prognosis, Radiography, Sensitivity and Specificity, Biomarkers, Tumor, Sequence Analysis, DNA, Mucin-1, Tumor Burden, Genome-Wide Association Study

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks